ReviewJournal of nuclear medicine : official publication, Society of Nuclear Medicine2014
Multimodality imaging of Alzheimer disease and other neurodegenerative dementias.
Review in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 69 citations in OpenAlex.
- Functional imaging constrained diffusion for brain PET synthesis from structural MRI.Medical image analysis · 2026Article
- A study on 18F-FDG PET/CT imaging assessment of the anti-aging efficacy of BMMSCs in the macaque brain.Stem cells translational medicine · 2026Article
- A lightweight CVTC model for accurate Alzheimer's MRI analysis and lesion annotation.NPJ digital medicine · 2026Article
- Clinical Role of Brain PET in Alzheimer Disease in the Era of Disease-Modifying Therapies.AJNR. American journal of neuroradiology · 2025Review
- Metallic Nanoparticles Applications in Neurological Disorders: A Review.International journal of biomaterials · 2025Review
- Identification of Autophagy-Related Candidate Genes in the Early Diagnosis of Alzheimer's Disease and Exploration of Potential Molecular Mechanisms.Molecular neurobiology · 2024Article
- Semiquantitative Approach to Amyloid Positron Emission Tomography Interpretation in Clinical Practice.World journal of nuclear medicine · 2023Article
- Novel App knock-in mouse model shows key features of amyloid pathology and reveals profound metabolic dysregulation of microglia.Molecular neurodegeneration · 2022Article
- Selective neurodegeneration of the hippocampus caused by chronic cerebral hypoperfusion: F-18 FDG PET study in rats.PloS one · 2022Article
- The Clinical Spectrum of Young Onset Dementia Points to Its Stochastic Origins.Journal of Alzheimer's disease reports · 2021Article
- F-18 FDG PET brain imaging in symptomatic arthroprosthetic cobaltism.European journal of nuclear medicine and molecular imaging · 2020Article
- Cerebral Small Vessel Disease and Alzheimer's Disease: A Review.Frontiers in neurology · 2020 · on this mapReview
- Evaluation of cell viability and metabolic activity of a 3D cultured human epidermal model using a dynamic autoradiographic technique with a PET radiopharmaceutical.Scientific reports · 2019Article
- Radiation dosimetry of [EJNMMI research · 2019Article
- Voxel-based comparison of brain glucose metabolism between patients with Cushing's disease and healthy subjects.NeuroImage. Clinical · 2018Article
- MEF2D Mediates the Neuroprotective Effect of Methylene Blue Against Glutamate-Induced Oxidative Damage in HT22 Hippocampal Cells.Molecular neurobiology · 2017Article
- Characterization of AD-like phenotype in aged APPSwe/PS1dE9 mice.Age (Dordrecht, Netherlands) · 2016Article
- Molecular cardiovascular imaging is ready for prime time: almost there.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2016Article
- The Potential of Metabolic Imaging.Seminars in nuclear medicine · 2016Review
- Amyloid PET imaging in multiple sclerosis: an (18)F-florbetaben study.BMC neurology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Neurodegenerative diseases, such as Alzheimer disease, result in cognitive decline and dementia and are a leading cause of mortality in the growing elderly population. These progressive diseases typically have an insidious onset, with overlapping clinical features early in the disease course that make diagnosis challenging. The neurodegenerative diseases are associated with characteristic, although not completely understood, changes in the brain: abnormal protein deposition, synaptic dysfunction, neuronal injury, and neuronal death. Neuroimaging biomarkers-principally regional atrophy on structural MR imaging, patterns of hypometabolism on (18)F-FDG PET, and detection of cerebral amyloid plaque on amyloid PET--are able to evaluate the patterns of these abnormalities in the brain to improve early diagnosis and help predict the disease course. These techniques have unique strengths and synergies in multimodality evaluation of the patient with cognitive decline or dementia. This review discusses the key imaging biomarkers from MR imaging, (18)F-FDG PET, and amyloid PET; the imaging features of the most common neurodegenerative dementias; the role of various neuroimaging studies in differential diagnosis and prognosis; and some promising imaging techniques under development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.